Selective Radiolabelled mGluR2/3 Ligands for PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current positron emission tomography (PET) radiotracers are inadequate for effectively imaging and quantifying Group II metabotropic glutamate receptors (mGluR2 and mGluR3) in tissues, necessitating the development of improved radiolabelled compounds for precise imaging and therapeutic targeting.
Innovation Solution
Development of novel radiolabelled mGluR2/3 ligands, specifically compounds of Formula (I) and their pharmaceutically acceptable salts or solvates, which are selectively radioactive and suitable for PET imaging, allowing for precise imaging and quantification of mGluR2/3 receptors in tissues and cells using positron-emission tomography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current PET radiotracers are used for imaging, then general tissue imaging is possible, but selective imaging and quantification of mGluR2/3 receptors cannot be achieved
Solution Approach 1:
The patent applies local quality by designing radioligands with specific molecular structures (Formula I) that have selective affinity for mGluR2/3 receptors. The radioligand comprises a specific ligand structure combined with a positron-emitting radionuclide, creating a tracer that locally targets and binds to mGluR2/3 receptors with high selectivity, enabling precise imaging and quantification of these specific receptors while leaving other receptor types unaffected.
2Adaptability or versatility
If non-selective radiotracers are used, then imaging coverage is broad, but specific mGluR2/3 receptor detection is inadequate
Solution Approach 1:
The patent applies parameter changes by modifying the chemical and physical parameters of the radiotracer to achieve selective mGluR2/3 receptor binding. This involves changing the ligand structure parameters (using specific chemical groups and configurations in Formula I) and radionuclide selection parameters (choosing positron-emitting isotopes with appropriate half-lives) to optimize both specificity and imaging precision for mGluR2/3 receptors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described compounds enable high-resolution imaging and quantification of mGluR2/3 receptors, facilitating improved diagnostic capabilities and potential therapeutic applications by providing selective and effective radiolabelled agents for PET imaging.
Implementation Method 1
The invention relates to novel, radiolabelled mGluR2/3 ligands, selective versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emission tomography (PET)
Implementation Method 2
using positron-emission tomography (PET) imaging system
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3B
AI summary
The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or 10 in vivo and to precursors of said compounds.